The difference that matters most between these two is what happens if you want it undone. Radiesse cannot be dissolved. Botox Cosmetic simply wears off.
Radiesse is calcium hydroxylapatite, or CaHA. It is a mineral, ground into tiny spheres 25 to 45 microns across and mixed into a gel of sterile water, glycerin and carboxymethylcellulose. The gel gives volume straight away. The body absorbs the gel over the first two to three months. The mineral spheres stay behind, and the body builds collagen around them before breaking them down into calcium and phosphate.
Hyaluronidase, the enzyme used to dissolve hyaluronic acid fillers, has no target in calcium hydroxylapatite. That is not a detail. It changes the whole risk calculation. It is the main reason to think carefully before choosing Radiesse over a dissolvable filler.
Botox Cosmetic is onabotulinumtoxinA. It does something entirely different. It relaxes muscle. It adds no volume. It has no reversal agent either. But it fades on its own. Both products are used in the lower face. No trial has compared them.
The 2006 approval covers "subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds". Hand augmentation was added in 2015, jawline contour for Radiesse (+) Lidocaine in 2021, and décolleté wrinkles at a 1:2 dilution with saline in 2026. Radiesse is not approved for jowls, marionette lines or the temples by name, and its labelling states safety and effectiveness in the lips has not been established.
Label doses in Botox Cosmetic Units only: 20 Units, 24 Units, 40 Units total for forehead with glabellar, and 26, 31 or 36 Units for platysma bands. These units do not convert to any other brand.
Hyaluronidase does nothing to calcium hydroxylapatite or to the carboxymethylcellulose carrier. Sodium thiosulfate is sometimes described online as an antidote; the largest preclinical study, run by the manufacturer, found no degradation of CaHA either in the laboratory or in animals, and did observe necrosis and haemorrhage. Documented options are time, saline infiltration with mechanical disruption, corticosteroids and, rarely, surgery.
In the nasolabial fold trial, 78.6% of Radiesse-treated folds scored at least a point better than the control side at 6 months. In an extension of that trial, 102 of the original 117 subjects were followed, and 40% of folds assessed at 30 months or more after the last treatment were graded "improved" or better — which means 60% were not. At the jawline, 75.6% responded at week 12 against 8.8% of controls, and about 67.3% of initial responders still had treatment success at week 48. The FDA's consumer page puts calcium hydroxylapatite at approximately 18 months. The label states only that safety beyond 3 years in the face and 2 years in the hand has not been investigated.
Hyaluronidase hydrolyses hyaluronic acid. That is the whole of what it does. Radiesse contains no hyaluronic acid. So the enzyme has nothing to act on. Not the calcium hydroxylapatite microspheres, and not the carboxymethylcellulose gel they sit in. A benchtop study of calcium hydroxylapatite in a simulated microvascular network found hyaluronidase produced "a minimal effect on occlusion". That study is a simulation. One of its authors works for the manufacturer.
Sodium thiosulfate circulates online as a Radiesse antidote. A 12-sample cadaveric porcine study and a handful of case reports support it. The largest preclinical study found no degradation of CaHA in the laboratory or in live animals. It did observe necrosis and haemorrhage after treatment. That study was run by the manufacturer, which has its own interest in the answer. A separate cadaveric study found CaHA still detectable in facial artery segments after 24 hours. That held regardless of the concentration used, with or without hyaluronidase. Sodium thiosulfate is not an established reversal agent.
What is left is time, saline infiltration with mechanical disruption through a cannula, intralesional corticosteroids, antibiotics if a biofilm is suspected, and surgical excision as a last resort. Neither the current Radiesse labelling nor the review literature names a reversal agent. The reviews list its absence as a known limitation.
Botox Cosmetic has no antidote either. The difference is that it fades in months and takes nothing with it.
Radiesse's jawline approval is about the contour of the jawline, not about jowls: The 2021 indication reads "deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21". Jowls are not named in any Radiesse approval, and filler does not lift skin that has become lax.
Marionette lines are not named either, though they plausibly sit inside the general wording "moderate to severe facial wrinkles and folds, such as nasolabial folds", where the parenthetical is an example rather than a limit. No pivotal trial has been run in marionette lines specifically. Radiesse is not approved for the temples, and its labelling states that safety and effectiveness in the lips has not been established, with published reports of nodules when it has been used there.
For the neck, the two products do different jobs. Botox Cosmetic has been approved for platysma bands since 18 October 2024, at 26, 31 or 36 Botox Cosmetic Units depending on band severity — that treats the cords that stand out when the neck is tensed, not the skin quality around them.
No trial has compared Radiesse against Botox Cosmetic: They treat different problems, so a comparison would not mean anything.
These signs can mean filler has entered a blood vessel. That is a rare event, and it is a medical emergency where time matters in hours.
Any change in vision — blurring, a dark patch, double vision or loss of sight in one eye, during or straight after an injection
Pain that is far worse than the procedure should cause, or pain that keeps building
Skin that turns white or pale in a patch soon after an injection, then goes dusky, blotchy or net-like
Weakness, drooping, slurred speech or confusion
Published guidance treats suspected blockage of the artery to the eye as a same-hour emergency and suspected skin blockage as a same-day emergency. In a review of 511 published blindness cases from 1906 to 2023, 68.2% of the 318 people with a recorded outcome had no recovery of vision, and no treatment used was significantly associated with improvement. Do not wait to see if it settles, and do not assume pain will warn you — in a survey of 52 experienced injectors, pain was mild or absent in 47% of the blocked-vessel events they described.
Swelling is still growing three or more days after treatment instead of settling
A lump appears and will not settle, or one appears weeks or months later
Redness spreads outward from the injection site, or the area becomes hot and tender
Tenderness, firmness or swelling turns up weeks after treatment, sometimes after an illness, a vaccination or dental work — this is a recognised delayed reaction
The product looks like it has moved out of the area that was treated